References
- Baize N, Abakar-Mahamat A, Mounier N, Berthier F, Caroli- Bosc FX (2009). Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens. Cancer Chemother Pharmacol, 64, 549. https://doi.org/10.1007/s00280-008-0903-7
- Cho BC, Kim JH, Kim CB, et al (2006). Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer. Oncol Rep, 15, 621.
- Chun JH, Kim HK, Lee JS, et al (2004). Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy. Jpn J Clin Oncol, 34, 8. https://doi.org/10.1093/jjco/hyh006
- Eisenhauer EA, Therasse P, Bogaerts J, et al (2009). J New response evaluation criteria in solid tumours: revised RECIST guideline (version 1. 1). Eur J Cancer, 45, 228. https://doi.org/10.1016/j.ejca.2008.10.026
- Giuliani F, Gebbia V, De Vita F, et al (2003). Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (G. O. I. M.). Anticancer Res, 23, 4219.
- Graziano F, Catalano V, Baldelli AM, et al (2000). A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Ann Oncol, 11, 1263. https://doi.org/10.1023/A:1008373814453
- Jeong J, Jeung HC, Rha SY, et al (2008). Phase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer. Ann Oncol, 19, 1135. https://doi.org/10.1093/annonc/mdn013
- Kim SH, Lee GW, Go SI, et al (2010). A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen. Am J Clin Oncol, 33, 572-6. https://doi.org/10.1097/COC.0b013e3181bead7b
- Kodera Y, Ito S, Mochizuki Y, et al (2007) A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric Cancer (CCOG0302 study). Anticancer Res, 27, 2667.
- Murad AM, Santiago FF, Petroianu, et al (1993). Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer, 72, 37-41. https://doi.org/10.1002/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P
- Park S, Lim D, Park K, et al (2011). A multicenter, randomized trial comparing second-line chemotherapy plus best supportive care (BSC) with BSC alone for pretreated advanced gastric cancer (AGC) (Abstract 4004). J Clin Oncol, 29, 257. https://doi.org/10.1200/JCO.2010.28.7078
- SEER Cancer Statistics http://www. seer. cancer. gov/statistics/ (Accessed on March 31, 2011).
- Seo HY, Kim DS, Choi YS, et al (2009). Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis. Cancer Chemother Pharmacol, 63, 433. https://doi.org/10.1007/s00280-008-0753-3
- Sym SJ, Ryu MH, Lee JL, et al (2008). Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane. Am J Clin Oncol, 31, 151. https://doi.org/10.1097/COC.0b013e31815878a2
- Therasse P, Arbuck SG, Eisenhauer EA, et al (2000). New guidelines to evaluate the response to treatment in solid tumors: European Organization for . Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 92, 205. https://doi.org/10.1093/jnci/92.3.205
- Thuss-Patience PC, Kretzschmar A, Bichev D, et al (2011). Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer-a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer, 47, 2306-14. https://doi.org/10.1016/j.ejca.2011.06.002
Cited by
- ) and Paclitaxel for Treatment of Patients with Metastatic Gastric Cancer vol.14, pp.4, 2013, https://doi.org/10.7314/APJCP.2013.14.4.2591
- Efficacy and Safety of Docetaxel or Epirubicin, Combined with Cisplatin and Fluorouracil, (DCF and ECF) Regimens as First Line Chemotherapy for Advanced Gastric Cancer: a Retrospective Analysis from Turkey vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6727
- Safety and continuity of second- and third-line therapy with paclitaxel or irinotecan for advanced and recurrent gastric cancer vol.2, pp.3, 2014, https://doi.org/10.3892/mco.2014.260
- Cost-effectiveness and safety of ramucirumab plus paclitaxel chemotherapy in the treatment of advanced and recurrent gastric cancer pp.1477-092X, 2017, https://doi.org/10.1177/1078155217707335
- Biomarker-Driven Therapy in Metastatic Gastric and Esophageal Cancer: Real-Life Clinical Experience vol.13, pp.2, 2018, https://doi.org/10.1007/s11523-017-0548-8